DESTINY-Breast08
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- NCT04556773 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DESTINY-Breast08 (trastuzumab deruxtecan plus capecitabine; trastuzumab deruxtecan plus durvalumab plus paclitaxel; trastuzumab deruxtecan plus capivasertib in HER2-low metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DESTINY-Breast08 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 10 | |
| X threads | 9 | |
| Podcasts | 4 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan; Durvalumab; Paclitaxel; Capivasertib; Anastrozole; Fulvestrant; Capecitabine
- Arms
- Module 1: T-DXd + capecitabine · Experimental
- Module 2: T-DXd + durvalumab + paclitaxel · Experimental
- Module 3: T-DXd + capivasertib · Experimental
- Module 4: T-DXd + anastrozole · Experimental
- Module 5: T-DXd + fulvestrant · Experimental
- Enrollment
- 138
- Primary outcomes
- Occurrence of adverse events (AEs)- Part 1
- Occurrence of serious adverse events (SAEs)- Part 1
- Occurrence of adverse events (AEs)- Part 2
- Occurrence of serious adverse events (SAEs)- Part 2
- Sponsor
- AstraZeneca with Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
- Start
- Dec 17, 2020
- Primary completion
- Aug 16, 2023
- Results posted
- No
- Registry record
- NCT04556773 · updated Aug 3, 2026